EU vs US Cosmetics Regulation: What Changes for One Product?

Short Answer

A product does not carry one universal cosmetics conclusion from the EU to the U.S. The same formula, label and safety file must be mapped to separate official sources, responsibilities and launch records for each market.

Key Takeaways

• Use separate source maps for the EU and U.S.
• Reuse evidence only when its scope is documented.
• Keep classification, label and submission questions visible by market.

Who This Applies To

This comparison is for brands and manufacturers planning one cosmetic product for both the European Union and the United States. It is a review framework, not a substitute for market-specific legal advice.

Regulatory Background

EU review follows Regulation (EC) No 1223/2009 and related requirements, while U.S. review uses the FD&C Act, MoCRA and Fair Packaging and Labeling Act together with applicable FDA material. These sources answer different questions. [20][01][02][03][15]

Key Requirements

Label, product identity, safety evidence and submission records should be reviewed against the source set for the selected market. A U.S. label or facility record cannot be treated as proof of EU compliance, and vice versa. [20][01][02][03][15]

• Create one controlled product and formula inventory.
• Split the evidence map into EU and U.S. workstreams.
• Compare identity, safety, label and submission questions.
• Mark reusable evidence and market-specific gaps.
• Assign a launch owner for each market.

Step-by-Step Comparison

Start with shared product facts, then branch the review by market. Read each market’s sources independently, compare the resulting obligations and record where the same evidence is sufficient, insufficient or irrelevant. Keep unresolved differences open until a reviewer closes them.

Common Mistakes

• Using one market’s label checklist for the other.
• Calling FDA listing or EU notification an approval.
• Treating shared formula evidence as proof every market obligation is complete.
• Writing a comparison without a source for both sides.

Practical Checklist

• EU and U.S. source sets are distinct.
• Shared evidence has a documented scope.
• Market-specific gaps have owners.
• Label and submission records are versioned.
• The comparison has a review date.

How EasyComply Can Help

EasyComply can keep one product inventory while generating separate EU and U.S. evidence views, so teams can compare the work without merging the underlying regulatory decisions.